Singapore markets close in 5 hours 21 minutes

Straits Times Index
3,312.87
-0.61(-0.02%)
Nikkei
39,346.92
+559.54(+1.44%)
Hang Seng
19,623.96
+70.35(+0.36%)
FTSE 100
8,420.26
-18.39(-0.22%)
Bitcoin USD
66,693.85
-552.45(-0.82%)
CMC Crypto 200
1,360.69
-13.15(-0.96%)

SPRY Nov 2024 10.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.6500

-0.2500

(-13.16%)

As of 12:34PM EDT. Market open.

GuruFocus.com
ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...
Exploring ARS Pharmaceuticals' Latest Financial Performance and Strategic Milestones
Simply Wall St.
ARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)
ARS Pharmaceuticals ( NASDAQ:SPRY ) First Quarter 2024 Results Key Financial Results Net loss: US$10.3m (loss narrowed...
GlobeNewswire
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
neffy® (epinephrine nasal spray) New Drug Application (NDA) and CRL response under review by FDA with anticipated review completion by early October 2024 Response submitted for neffy Marketing Authorization Application (MAA) to EMA’s CHMP; CHMP opinion expected in the second quarter of 2024 Preparing to initiate outpatient study of neffy for urticaria (hives) in second half of 2024 $223.6 million in cash and securities as of March 31, 2024, providing an expected operating runway of at least thre